Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs Axogen Inc (AXGN) Price & Performance

Alexandria Real Estate Equities IncTrade
Axogen IncTrade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs Axogen Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.06 (market cap $8.28B), while Axogen Inc trades at $49.66 (market cap $2.61B). The key difference: Alexandria Real Estate Equities Inc is far larger — about 3.2× Axogen Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.99% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.

AREAXGN
Market Cap
$8.28B$2.61B
Sector
Real EstateTechnology
52-Week High
$87.45$48.48
52-Week Low
$40.41$14.16
Enterprise Value
$20.98B$2.52B
Dividend Yield
5.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $48.07, down 0.58% on the day, with a bearish technical signal and mixed earnings. The stock shows negative profitability metrics, including a net income margin of -37.12% and ROE of -6.29%, though it beat FFO estimates in Q2 2026. Recent news highlights leasing momentum and a narrowed full-year FFO guidance range, while a pending lawsuit adds uncertainty.

The outlook remains cautious due to weak earnings and high debt, but the stock trades below book value, offering potential value. Risks include ongoing losses, litigation, and real estate market volatility. Analyst consensus is mixed with a $53.71 price target, suggesting modest upside if operational improvements materialize.

Axogen Inc

AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.

Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About Axogen Inc

Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.

Read more on AXGN